Exousia Bio, Inc. (LMMY) stock: key figures, P/E, revenue and dividend
Consumer Discretionary · United States
Exousia Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3,750.00 USD |
| Gross profit | -3,501.00 USD |
| EBIT | 51,395.00 USD |
| Net income | 51,395.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Exousia Bio, Inc.
Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026. The company was incorporated in 2022 and is based in Saint Petersburg, Florida.
More stocks
- SATIVUS TECH CORP. (SATT)
- Hestia Insight Inc. (HSTA)
- LUDWIG ENTERPRISES, INC. (LUDG)
- Omnitek Engineering Corp (OMTK)
- CLOUDASTRUCTURE, INC. (CSAI)
- Bright Mountain Media, Inc. (BMTM)
- Triller Group Inc. (ILLR)
- Digital Brand Media & Marketing Group, Inc. (DBMM)
- IIOT-OXYS, Inc. (ITOX)
- NEUTRA CORP. (NTRR)
- Mitesco, Inc. (MITI)
- Green Planet Bio Engineering Co. Ltd. (GPLB)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.